Satellite Symposia

Satellite symposia descriptions will be posted as they are confirmed. Please visit this page regularly for updated information.  
 

Thursday, April 20

Satellite Symposium - Pfizer Injectables (18:30 - 20:00)

The Use of LMWH in Renally Impaired Patients with Cancer

Wendy Lim, McMaster University, Hamilton, ON

Low molecular weight heparins (LMWHs) have largely replaced unfractionated heparin (UFH) in many clinical settings. At the end of this session, participants will have a better understanding when LMWHs or UFH are used in patients. Also, participants will be informed on the latest available evidence of the used of LMWH with renally impaired patients with cancer. 

Friday, April 21

Satellite Symposium - Apobiologix (07:00 - 08:30)

How to Maximize the Value of Biosimilars in Canada?

Kathy Gesy, Saskatchewan Cancer Agency, Saskatoon, SK
Pedro Gascon, Barcelona University Medical School, Barcelona, Spain

Biologic medications dramatically improve patients’ quality of life. For payers, drug spend on biologics is growing significantly. Biosimilars help contribute to overall sustainability. With the approval of a growing number of biosimilars in Canada, patient advocacy groups, pharmacists, nurses, physicians and payers are evaluating biosimilar policies and related practical considerations. This program explores how to maximize the value of biosimilars in Canada and includes topics such as how biosimilars can be adopted into an institution, practical challenges in adopting biosimilars, solutions to overcome practical barriers, patient support and education.

Satellite Symposium - Amgen (08:45-10:15)

Advances in the Treatment of Metastatic Colorectal Cancer and the Role of Multidisciplinary Management in Optimizing Patient Outcomes 

Tom McFarlane, University of Waterloo, Kitchener, ON
Oliver F. Bathe, Tom Baker Cancer Centre, Calgary, AB
Scot Dowden, Tom Baker Cancer Centre, Calgary, AB
 
Systemic therapy and surgical approaches to managing metastatic colorectal cancer (mCRC) continue to evolve with increased personalization of therapy according patient and tumour features. 
 
Learning Objectives:
  1. Examine the role of biomarkers and primary tumour location in treatment decisions, based on the latest clinical study findings; 
  2. Review current guidance around the surgical management of mCRC, with a focus on resection of liver-limited metastases; and
  3. Recognize the elements of multidisciplinary care that are integral to achieving optimal outcomes for patients with mCRC.

Satellite Symposium - Amgen (10:30 - 12:00)

Biosimilars in Oncology: From Cell Cultures to Clinical Considerations 

Michael Leblanc, The Moncton Hospital, Moncton, NB
Annick Dufour, Réseau Cancer Montérégie, Montreal, QC
Sandy Sehdev, The Ottawa Hospital Cancer Centre, Ottawa, ON
 
Biologic drugs have significantly changed the treatment landscape in oncology, in terms of efficacy, toxicity management, and drug access support. The introduction of biosimilar products will also bring new benefits and challenges to patient management.
 
Learning Objectives:
  1. Examine the similarities and differences between innovator products and biosimilars, in terms of the manufacturing process and final product;
  2. Gain an understanding of the scientific evidence and regulatory requirements for marketing authorization of biosimilars; and
  3. Identify practical and clinical considerations for initiating or switching to a biosimilar, and the implications for patient management.

Satellite Symposium - Merck (12:15 - 13:45)

 
Scott Edwards, Dr. H. Bliss Murphy Cancer Center, St. John’s, NL
Sean Hopkins, Simcoe Muskoka Regional Cancer Program, Barrie, ON
 
At a time when new treatment options are becoming available for the treatment of many cancers, the pharmacist is well placed and plays an instrumental part in not only recognizing and managing adverse events but also educating other members of the interdisciplinary team. This conference will demonstrate the value of collaboration with other healthcare professionals while sharing best practices of communication and management of immune-checkpoint inhibitors and immuno-related toxicities with patients and care givers.
 
Learning Objectives:
  1. Summarize the latest practice-changing evidence affecting the treatment of patients with metastatic melanoma or lung cancer under immunotherapy (monotherapy or combination);
  2. Discuss the role of pharmacists within an interdisciplinary team in recognizing and managing immuno-related toxicities; and
  3. Review best practices in the effective management of immuno-related AEs.

Satellite Symposium - Pfizer Oncology (14:00 - 15:30)

The Evolving Landscape of Patient Management in Hormone Positive Breast Cancer

Karen Gelmon, Vancouver Centre, BCCA, Vancouver, BC

Learning Objectives:

  1. Describe therapeutic approaches for the treatment of hormone-positive breast cancer: past history to the present day of endocrine therapy;
  2. Understand the implications of the evidence on patient management; and
  3. Discuss the impact of health and well-being initiatives on both patient and healthcare professionals.

Satellite Symposium - Hoffmann - La Roche (15:45 - 17:15)

HER2+ Early Breast Cancer Therapy: Good, Better, Best - Never Let it Rest!

Anil Abraham Joy, University of Alberta, Edmonton, AB
Colleen Olson, Saskatoon Cancer Centre, Saskatoon, SK
 
Breast cancer remains the most commonly diagnosed cancer in women and is the leading cause of cancer-related deaths. Despite current advances in HER2-positive early breast cancer treatments, up to one in three women with HER2-positive early breast cancer will develop metastatic disease. This session will focus on the evolution of HER2-targeted therapies in early breast cancer and the potential role of novel agents in HER2-positive breast cancer form the perspective of a multi-disciplinary team.  
 
Learning Objectives:
  1. Review the historical outcomes in the pre-trastuzumab era, the trastuzumab revolution and optimization of trastuzumab therapy;
  2. Examine the role of novel agents/therapeutic strategies in early HER2-positive breast cancer;
  3. Understand the mechanism of action, common toxicities, and pharmacy consideration in administration of HER-targeted therapies; and
  4. Discuss the role of pharmacists in early breast cancer patient practice

Saturday, April 22

Satellite Symposium - Pfizer Injectables (07:00 - 08:30)

 
Eric Kastango, Clinical IQ LLC, Florham Park, USA
 
This presentation will explore what pharmacists and technicians will need to know to understand and comply with applicable rules and regulations as it relates to compounding and occupational exposure to hazardous drugs.
 
Learning Objectives:
  1. Describe the current regulatory environment in the US and Canada for pharmacies/pharmacists/technicians;
  2. Understand the major requirements of the USP Chapter <800>-Hazardous Drugs - Handling in the Healthcare Setting; 
  3. Understand the major requirements of the NAPRA Model Standards for Pharmacy Compounding of Hazardous Sterile Preparations; and
  4. Describe risk mitigation strategy to provide safe compounded medication while protecting healthcare workers.

Sunday, April 23

Satellite Symposium - Astellas (07:00 - 08:30)

Wake Up: Get a Move on Managing Fatigue in Oncology Patients and Recognizing the Pharmacist’s Role

Naveen Basappa, Cross Cancer Institute, Edmonton, AB
Kerry S. Courneya, University of Alberta, Edmonton, AB
Khristine Wilson, Allan Blair Cancer Centre, Regina, SK
 
Learning Objectives:
  1. Describe the prevalence of fatigue in oncology patients and how it impacts patient quality of life using a hormonal oral agent case example; 
  2. Discuss exercise-based strategies to improve the management of fatigue in oncology patients and review data on the impact of physical activity on patient quality of life; and
  3. Recognize the role of pharmacists in counselling patients, monitoring fatigue, and the importance of collaboration with other HCPs to optimize patient management. 

Satellite Symposium - BD Canada (12:30 - 14:00)

NAPRA Model Standards for Hazardous Drugs are here: Now what?

Marshall Moleschi, Ontario College of Pharmacists, Toronto, ON

With the ever changing landscape of Pharmacy practice, USP 800 and NAPRA standards look to ensure hospital pharmacies operate in a safe manner for pharmacists, health care workers and patients. This presentation will look at the practice changes of today with considerations for the future. 
 
Learning Objectives:
  1. Describe how the standards were designed with an in-depth knowledge of the Canadian Healthcare Model;
  2. What Canadian patient’s and Health Care workers expect, with consideration of the service areas from urban, to rural to remote; 
  3. How the NAPRA model standards will evolve; and
  4. Strategies for being compliant and meeting the standards within your operating budget.